Precision detection solutions for clinical application of hematological tumors using MRD and NGS technologies
The abbreviation of minimal residual disease (MRD) refers to the presence of very few tumor cells or tiny lesions in the patient's body after anti-cancer treatment. These cells or lesions cannot be detected by morphological or imaging methods and require the use of more sensitive methods.
MRD is the direct cause of tumor recurrence.
In hematological tumors, especially leukemia (especially acute leukemia), MRD is one of the commonly used clinical monitoring indicators. Its significance in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), acute mixed leukemia (MPAL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), as well as in pre- and post-transplantation monitoring has been fully affirmed.
PanOne MRD utilizes multi-parameter flow cytometry (MFC) combined with next-generation sequencing (NGS) technology to achieve highly sensitive detection of minimal residual disease in hematological malignancies.
Comprehensive genomic profiling solution for hematological malignancies using targeted NGS panels.
Aperbio Technologies is a national high-tech enterprise and a leading talent enterprise in Suzhou. We innovate life science research tools and medical diagnostic products, focusing on the research and development of precision medicine solutions. Our mission is to provide cutting-edge molecular diagnostic technologies to improve patient outcomes in oncology and infectious diseases.
For more information about our Blood Diseases detection solutions, please contact us: